Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

BACKGROUND: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival ana...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Guren, Tormod Kyrre, Thomsen, Maria, Kure, Elin H, Sorbye, Halfdan, Glimelius, Bengt, Pfeiffer, Per, Österlund, Pia, Sigurdsson, Fridbjörn, Lothe, Inger Marie Bowitz, Dalsgaard, Astrid Marie, Skovlund, Eva, Christoffersen, Thoralf, Tveit, Kjell Magne
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2017
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482736/
https://ncbi.nlm.nih.gov/pubmed/28399112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.93
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы